RTP Mobile Logo
Select Publications

Annala M et al. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: A multicentre, randomised, open-label, phase II trial. Ann Oncol 2021;32(7):896-905. Abstract

Attard G et al. Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. ESMO 2021;Abstract LBA4_PR.

Bjartell A et al. Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the first- or second-line treatment for metastatic castration-resistant prostate cancer: Data from the Prostate Cancer Registry. Target Oncol 2021;16(3):357-67. Abstract

Colomba E et al. ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC). ASCO 2021;Abstract 5046.

Feng FY et al. Association of molecular subtypes with differential outcome to apalutamide treatment in nonmetastatic castration-resistant prostate cancer. JAMA Oncol 2021;7(7)1005-14. Abstract

Finelli A et al. Comparison of joint and landmark modeling for predicting cancer progression in men with castration-resistant prostate cancer: A secondary post hoc analysis of the PREVAIL randomized clinical trial. JAMA Netw Open 2021;4(6):e2112426. Abstract

Gillessen S et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. ASCO 2021;Abstract 5002.

Loehr A et al. Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study. Clin Cancer Res 2021;[Online ahead of print]. Abstract

Merseburger AS et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: A pragmatic guide for clinicians. Eur Urol 2021;79(4):519-29. Abstract

Sartor O et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091-103. Abstract

Sweeney CJ et al. Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy. Eur Urol 2021;80(3):275-9. Abstract

Tukachinsky H et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms. ASCO Genitourinary Cancers Symposium 2021;Abstract 25.

Tukachinsky H et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin Cancer Res 2021;27(11):3094-105. Abstract

van der Zande K et al. First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC). ASCO 2021;Abstract 5059.